NovoCure Limited NVCR
Updated: 17 Jun 2026
No signal published yet
We already track NovoCure and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow NovoCure Limited? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow NovoCure free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On April 30, 2026, NovoCure reported Q1 revenue of $174 million and raised its full-year 2026 revenue guidance to $690–$710 million. The company recently launched Optune Pax in the U.S. following FDA approval for the treatment of pancreatic cancer.
What Firelda Watch includes for NovoCure Limited
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow NovoCure Limited? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow NovoCure free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more